Blackberry Limited (BB) Opens the Market
Toronto, Ontario–(Newsfile Corp. – February 4, 2025) – John Giamatteo, Chief Executive Officer, BlackBerry Limited, Tim Foote, Chief Financial Officer, BlackBerry Limited (“BlackBerry ” or the “Company”) (TSX:BB) and their team, joined Dani Lipkin, Managing Director, Global Innovation Sector, Toronto Stock Exchange (TSX), to open the market to celebrate the Company’s long-lasting relationship with Toronto Stock Exchange.
Cannot view this video? Visit:
https://www.youtube.com/watch?v=K268A2ctLpg
BlackBerry began trading on TSX in October 1997 under the name Research in Motion and 12 years ago today marks the change in name and ticker to BlackBerry (TSX:BB). BlackBerry (NYSE:BB) (TSX:BB) provides enterprises and governments the intelligent software and services that power the world around us. Based in Waterloo, Ontario, the company’s high-performance foundational software enables major automakers and industrial giants alike to unlock transformative applications, drive new revenue streams and launch innovative business models, all without sacrificing safety, security, and reliability. With a deep heritage in Secure Communications, BlackBerry delivers operational resiliency with a comprehensive, highly secure, and extensively certified portfolio for mobile fortification, mission-critical communications, and critical events management.
MEDIA CONTACT:
BlackBerry Media Relations
+1 (519) 597-7273
mediarelations@BlackBerry.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/239570
Related news for (BB)
- NB Bancorp, Inc. and Provident Bancorp, Inc. Announce Mailing of Stock/Cash Election Form
- Don’t Miss Out: MoBot’s Latest Stock Updates 10/02/25 03:00 PM
- MoBot alert highlights: NASDAQ: CIGL, NASDAQ: YYAI, NYSE: BURU, NYSE: BBBY, NASDAQ: LPTX (10/02/25 02:00 PM)
- AbbVie Submits Biologics License Application (BLA) to U.S. FDA for Pivekimab sunirine (PVEK) – an Investigational Antibody-Drug Conjugate (ADC) to Treat Rare Cancer with Limited Treatment Options
- AbbVie Announces UK Pricing Strategy for ELAHERE® (mirvetuximab soravtansine-gynx)